VERACYTE, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Veracyte, Inc. on January 12, 2015. The report discloses a corporate governance change involving the election of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On January 12, 2015, the Board of Directors elected Robert S. Epstein, M.D., M.S., to the Board of Directors. Dr. Epstein will also serve on the Nominating and Corporate Governance Committee and the Compliance Committee. He is a strategic consultant with extensive expertise in pharmacoeconomics and health outcomes research, having previously served as president of the Medco-UBC Division and chief research and development officer of Medco Health Solutions, Inc.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors. Dr. Epstein's compensation will align with the standard cash and equity compensation paid to non-employee directors as described in the Company's 2014 proxy statement.
Key Facts for Investor Verification
- Robert S. Epstein, M.D., M.S., was elected to the Board of Directors effective January 12, 2015.
- Dr. Epstein will serve on the Nominating and Corporate Governance Committee and the Compliance Committee.
- Dr. Epstein currently serves on the boards of Illumina, Inc., Proteus Digital Health, Inc., and Fate Therapeutics, Inc.
- His compensation is consistent with existing non-employee director arrangements.